Bio Preventive Medicine Corp.(TW:6810)
NT$22.75+0.80 (+3.64%)
TW:6810
Bio Preventive Medicine Corp. financials statements
NT$22.75
At close:+0.80 (+3.64%)
Bio Preventive Medicine Corp. (6810) Ratios
Bio Preventive Medicine Corp. Ratios
TW:6810's free cash flow for Q2 2026 was NT$-48.88M. For the 2026 fiscal year, TW:6810's free cash flow was decreased by NT$-210.00K and operating cash flow was NT$-48.67M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.35 | 17.52 | 5.09 | 4.97 | 7.48 |
| Quick Ratio | 12.30 | 17.45 | 5.02 | 4.91 | 7.41 |
| Cash Ratio | 11.59 | 16.86 | 4.42 | 4.29 | 1.94 |
| Solvency Ratio | -0.79 | -0.65 | -0.52 | -0.41 | -3.08 |
| Operating Cash Flow Ratio | -4.38 | -3.20 | -3.41 | -2.86 | -3.06 |
| Short-Term Operating Cash Flow Coverage | -17.62 | -11.94 | -8.68 | -6.63 | -106.23 |
| Net Current Asset Value | NT$ 149.08M | NT$ 243.76M | NT$ -30.78M | NT$ -37.51M | NT$ 94.60M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.24 | 0.20 | 0.43 | 0.45 | 0.04 |
| Debt-to-Equity Ratio | 0.33 | 0.26 | 0.81 | 0.87 | 0.04 |
| Debt-to-Capital Ratio | 0.25 | 0.21 | 0.45 | 0.46 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.24 | 0.20 | 0.43 | 0.45 | 0.00 |
| Financial Leverage Ratio | 1.38 | 1.30 | 1.89 | 1.94 | 1.11 |
| Debt Service Coverage Ratio | -11.64 | -8.87 | -6.27 | -5.86 | -67.67 |
| Interest Coverage Ratio | -37.94 | -28.39 | -26.85 | -76.22 | -265.77 |
| Debt to Market Cap | 0.09 | 0.10 | 0.10 | 0.12 | 0.00 |
| Interest Debt Per Share | 2.11 | 3.11 | 3.42 | 3.87 | 0.19 |
| Net Debt to EBITDA | 1.59 | 3.21 | -0.51 | -0.74 | 0.50 |
| Profitability Margins | |||||
| Gross Profit Margin | -186.75% | 96.42% | -592.55% | 89.48% | 88.65% |
| EBIT Margin | -3832.05% | -687.47% | -5842.88% | -3215.94% | -7680.62% |
| EBITDA Margin | -3557.59% | -622.60% | -5160.68% | -2469.13% | -5230.62% |
| Operating Profit Margin | -3832.05% | -697.44% | -6006.95% | -3252.69% | -7680.62% |
| Pretax Profit Margin | -3800.80% | -712.04% | -6066.64% | -3258.61% | -7709.52% |
| Net Profit Margin | -3800.80% | -712.04% | -6066.64% | -3258.61% | -7709.52% |
| Continuous Operations Profit Margin | -3800.80% | -712.04% | -6066.64% | -3258.61% | -7709.52% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 99.18% | 102.09% | 100.99% | 100.18% | 100.38% |
| Return on Assets (ROA) | -23.48% | -16.53% | -27.69% | -25.97% | -43.99% |
| Return on Equity (ROE) | -32.50% | -21.51% | -52.37% | -50.48% | -48.74% |
| Return on Capital Employed (ROCE) | -24.94% | -16.86% | -29.47% | -27.88% | -48.46% |
| Return on Invested Capital (ROIC) | -24.62% | -16.67% | -28.63% | -26.98% | -46.62% |
| Return on Tangible Assets | -24.01% | -16.90% | -29.25% | -27.65% | -50.03% |
| Earnings Yield | -8.63% | -8.22% | -6.29% | -6.74% | -5.96% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.98 | 20.39 | 8.27 | 8.92 | 3.21 |
| Payables Turnover | 50.22 | 3.67 | 70.90 | 0.89 | 0.00 |
| Inventory Turnover | 6.57 | 0.31 | 6.76 | 0.18 | 0.10 |
| Fixed Asset Turnover | 0.02 | 0.08 | 0.01 | 0.01 | 0.04 |
| Asset Turnover | 0.01 | 0.02 | 0.00 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 0.01 | 0.06 | 0.02 | 0.03 | 0.01 |
| Cash Conversion Cycle | 121.53 | 1079.72 | 92.98 | 1682.61 | 3826.53 |
| Days of Sales Outstanding | 73.22 | 17.90 | 44.11 | 40.91 | 113.85 |
| Days of Inventory Outstanding | 55.58 | 1161.36 | 54.01 | 2052.93 | 3712.68 |
| Days of Payables Outstanding | 7.27 | 99.55 | 5.15 | 411.22 | 0.00 |
| Operating Cycle | 128.80 | 1179.26 | 98.13 | 2093.84 | 3826.53 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.92 | -1.89 | -1.85 | -1.72 | -1.45 |
| Free Cash Flow Per Share | -1.95 | -1.90 | -1.94 | -6.53 | -1.56 |
| Dividend Paid and CapEx Coverage Ratio | -49.08 | -108.87 | -35.68 | -0.36 | -14.24 |
| Capital Expenditure Coverage Ratio | -49.08 | -108.87 | -35.68 | -0.36 | -14.24 |
| Operating Cash Flow Coverage Ratio | -0.93 | -0.62 | -0.55 | -0.45 | -7.81 |
| Operating Cash Flow to Sales Ratio | -36.06 | -5.44 | -52.07 | -25.09 | -51.41 |
| Free Cash Flow Yield | -8.35% | -6.34% | -5.64% | -19.68% | -4.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -11.58 | -12.15 | -15.89 | -14.82 | -16.78 |
| Price-to-Sales (P/S) Ratio | 440.47 | 86.64 | 963.92 | 483.79 | 1293.08 |
| Price-to-Book (P/B) Ratio | 3.77 | 2.62 | 8.32 | 7.49 | 8.17 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.97 | -15.77 | -17.74 | -5.08 | -23.50 |
| Price-to-Operating Cash Flow Ratio | -12.22 | -15.91 | -18.51 | -19.28 | -25.15 |
| Price-to-Earnings Growth (PEG) Ratio | 0.64 | -0.85 | 4.45 | -5.38 | 36.74 |
| Enterprise Value Multiple | -10.79 | -10.71 | -19.19 | -20.34 | -24.22 |
| Enterprise Value | 1.01B | 820.02M | 1.20B | 1.09B | 1.10B |
| EV to EBITDA | -10.79 | -10.71 | -19.19 | -20.34 | -24.22 |
| EV to Sales | 383.80 | 66.68 | 990.25 | 502.15 | 1267.07 |
| EV to Free Cash Flow | -10.43 | -12.14 | -18.22 | -5.27 | -23.03 |
| EV to Operating Cash Flow | -10.64 | -12.25 | -19.02 | -20.01 | -24.65 |
| Tangible Book Value Per Share | 6.03 | 11.13 | 3.71 | 3.91 | 3.87 |
| Shareholders’ Equity Per Share | 6.21 | 11.46 | 4.12 | 4.43 | 4.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.05 | 0.35 | 0.04 | 0.07 | 0.03 |
| Net Income Per Share | -2.02 | -2.47 | -2.16 | -2.24 | -2.18 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.99 | 1.04 | 1.04 | 1.01 | 1.00 |
| Research & Development to Revenue | 17.72 | 3.81 | 33.56 | 14.52 | 50.31 |
| SG&A to Revenue | 18.73 | 4.13 | 25.45 | 12.88 | 27.56 |
| Stock-Based Compensation to Revenue | 0.00 | 0.79 | 0.56 | 0.00 | 0.00 |
| Income Quality | 0.95 | 0.76 | 0.86 | 0.77 | 0.67 |
Currency in TWD
